Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933068 | 0.92 | CA9 (0.42) | CHRNA7FAAHMGLLNPC1RAB9A | |
| SCHEMBL2913900 | 0.86 | ALDH1A1 (0.44) | CHRNA7FAAHMGLLNPC1RAB9A | |
| SCHEMBL5516387 | 0.84 | ALOX5 (0.43) | CHRNA7FAAHLMNATP53CA9 | |
| SCHEMBL27619816 | 0.84 | RPA1 (0.45) | SMN1; SMN2KMT2A | |
| SCHEMBL5521156 | 0.84 | ALDH1A1 (0.52) | CHRNA7FAAHMGLLNPC1RAB9A | |
| SCHEMBL5527972 | 0.82 | ALOX5 (0.37) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL5522528 | 0.81 | ALOX5 (0.40) | FAAHMGLLRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL5269059 | 0.81 | CA9 (0.43) | CHRNA7FAAHMGLLRAB9ASMN1; SMN2 | |
| SCHEMBL2915553 | 0.81 | TP53 (0.40) | CHRNA7FAAHMGLLLMNATP53 | |
| SCHEMBL2919032 | 0.81 | CA9 (0.57) | CHRNA7FAAHMGLLLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | CHRNA7 4696/4885FAAH 1345/4885MGLL 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.